All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your GvHD Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2019-05-28T12:43:37.000Z

Ruxolitinib approved by the FDA for steroid refractory acute GvHD

May 28, 2019
Share:

Bookmark this article

The US Food and Drug Administration has approved ruxolitinib for patients aged 12 years and older with steroid refractory acute graft-versus-host-disease (aGvHD). Results of an open-label, single-arm, multicenter study showed that a combination of ruxolitinib with corticosteroids induced a 57% overall response rate (ORR), and a complete response (CR) of 31% at 28 days.

In February 2019, the FDA  added 3 months to the review period for the drug, to allow the agency to review additional data requested from the manufacturers, Incyte. The drug was previously approved by the FDA as treatment for patients with intermediate or high-risk myelofibrosis. 

The trial (NCT 02953678) enrolled 49 patients with steroid refractory aGvHD, grades II—IV, occurring after hematopoietic stem cell transplantation. The initial dose administered was 5mg, which could be increased to 10mg, after three days in the absence of toxicity.

The primary end-points of the study were ORR, CR, very good partial response (VGPR), or partial response (PR). On day 28, ORR was 100% for grade II GvHD, 40.7% for grade III, and 44.4% for grade IV GvHD. The median response duration was 16 days (95% CI; 9—83), and was calculated from day 28 response to progression, new salvage therapy for aGvHD or death from any cause. The median time from day 28 response to either death or need for new therapy for aGvHD, was 173 days (95% CI).

Common haematological adverse reactions in patients (>50% incidence) were anemia, thrombocytopenia, and neutropenia, with the most common nonhematologic adverse reactions being infections and edma (>50%).

  1. Jagasia M, et al. Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials. Immunotherapy. 2018 Jan 9. 10(5):391-402.

Newsletter

Subscribe to get the best content related to GvHD delivered to your inbox